BI 638683
Latest Information Update: 28 Mar 2018
At a glance
- Originator Boehringer Ingelheim
- Class
- Mechanism of Action CCR1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 28 Mar 2018 No recent reports of development identified for phase-I development in Rheumatoid-arthritis(In volunteers) in Germany (PO, Liquid)
- 20 Sep 2010 Phase-I clinical trials in Rheumatoid arthritis (in healthy volunteers) in Germany (PO)
- 03 Sep 2010 Preclinical trials in Undefined indication in Germany (PO)